Search

Your search keyword '"Solène Dauby"' showing total 8 results
Start Over Author "Solène Dauby"
8 results on '"Solène Dauby"'

1. Using quantitative magnetic resonance imaging to track cerebral alterations in multiple sclerosis brain: A longitudinal study

Author

Nora Vandeleene, Camille Guillemin, Solène Dauby, Florence Requier, Maëlle Charonitis, Daphne Chylinski, Evelyne Balteau, Pierre Maquet, Emilie Lommers, and Christophe Phillips

Subjects
longitudinal analysis, multiple sclerosis, quantitative MRI, relaxometry, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Abstract Introduction Quantitative MRI quantifies tissue microstructural properties and supports the characterization of cerebral tissue damages. With an MPM protocol, 4 parameter maps are constructed: MTsat, PD, R1 and R2*, reflecting tissue physical properties associated with iron and myelin contents. Thus, qMRI is a good candidate for in vivo monitoring of cerebral damage and repair mechanisms related to MS. Here, we used qMRI to investigate the longitudinal microstructural changes in MS brain. Methods Seventeen MS patients (age 25–65, 11 RRMS) were scanned on a 3T MRI, in two sessions separated with a median of 30 months, and the parameters evolution was evaluated within several tissue classes: NAWM, NACGM and NADGM, as well as focal WM lesions. An individual annual rate of change for each qMRI parameter was computed, and its correlation to clinical status was evaluated. For WM plaques, three areas were defined, and a GLMM tested the effect of area, time points, and their interaction on each median qMRI parameter value. Results Patients with a better clinical evolution, that is, clinically stable or improving state, showed positive annual rate of change in MTsat and R2* within NAWM and NACGM, suggesting repair mechanisms in terms of increased myelin content and/or axonal density as well as edema/inflammation resorption. When examining WM lesions, qMRI parameters within surrounding NAWM showed microstructural modifications, even before any focal lesion is visible on conventional FLAIR MRI. Conclusion The results illustrate the benefit of multiple qMRI data in monitoring subtle changes within normal appearing brain tissues and plaque dynamics in relation with tissue repair or disease progression.

Published
2023
Full Text
View/download PDF

2. Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Author

Nicolas Lambert, Solène Dauby, Dominique Dive, Bernard Sadzot, and Pierre Maquet

Subjects
progressive multifocal leukoencephalopathy, immunotherapy, JC virus, immune reconstitution inflammatory syndrome, Belgium, viruses, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.

Published
2022
Full Text
View/download PDF

4. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort

Author

Solène, Dauby, Dominique, Dive, Laurence, Lutteri, Cécile, Andris, Isabelle, Hansen, Pierre, Maquet, and Emilie, Lommers

Subjects
Adult, Aquaporin 4, Male, Optic Neuritis, Neuromyelitis Optica, Prognosis, Retina, Cohort Studies, Myelin-Associated Glycoprotein, Belgium, Immunoglobulin G, Humans, Female, Myelin-Oligodendrocyte Glycoprotein, Age of Onset, Autoantibodies, Retrospective Studies
Abstract

To emphasize physio-pathological, clinical and prognosis differences between conditions causing serious and sometimes very similar clinical manifestations: anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies related diseases, and seronegative NMOSD (neuromyelitis optica spectrum disorders).Based on Wingerchuk et al. (Neurology 85:177-189, 2015) criteria for NMOSD and on those more recently proposed by Jarius et al. (J Neuroinflammation 15:134, 2018) for MOGAD (MOG associated disorders), we retrospectively surveyed 10 AQP4-NMOSD, 8 MOGAD and 2 seronegative NMOSD, followed at the specialized neuroimmunology unit of the CHU Liège.Female predominance was only observed in AQP4 group. Age at onset was 37.8 and 27.7 years old for AQP4-NMOSD and MOGAD respectively. In both groups, the first clinical event most often consisted of optic neuritis (ON), followed by isolated myelitis. Fifteen of our 20 patients encountered a relapsing course with 90% relapses in AQP4-NMOSD, 62.5% in MOGAD and 50% in seronegative group, and a mean period between first and second clinical event of 7.1 and 4.8 months for AQP4-NMOSD and MOGAD, respectively. In total we counted 54 ON, with more ON per patient in MOGAD. MOG-associated ON mainly affected the anterior part of the optic nerve with a papilledema in 79.2% of cases. Despite a fairly good visual outcome after MOG-associated ON, retinal nerve fibre layer (RNFL) thickness decreased, suggesting a fragility of the optic nerve toward further attacks.As observed in larger cohorts, our MOGAD and AQP4-NMOSD cases differ by clinical and prognostic features. A better understanding of these diseases should encourage prompt biological screening and hasten proper diagnosis and treatment.

Published
2020

6. The frequency and influence of dementia risk factors in prodromal Alzheimer's disease

Author

Alexandre de Mendonça, Gerald Novak, Giovanni B. Frisoni, Philip Scheltens, Harald Hampel, Hilkka Soininen, Silvia Morbelli, Peter Johannsen, Alberto Lleó, Myriam Alexander, Ellis Niemantsverdriet, Mark Forrest Gordon, Solène Dauby, Mira Didic, Samantha Galluzzi, Angelika Wientzek, Rik Vandenberghe, Isabel Santana, Frans R.J. Verhey, Isabelle Bos, Yvonne Freund-Levi, Sebastiaan Engelborghs, Stephanie J.B. Vos, Alexander Drzezga, Wolfgang Maier, Johannes Kornhuber, Pieter Jelle Visser, Daniel Alcolea, Ellen Elisa De Roeck, Dina Silva, Inês Baldeiras, Jens Wiltfang, Oliver Peters, Anders Wallin, Eric Salmon, Sanna-Kaisa Herukka, E. Rüther, Magda Tsolaki, Preciosa M. Coloma, Christine Bastin, Lutz Frölich, Bart N.M. van Berckel, Åsa K. Wallin, Arto Nordlund, Flavio Nobili, Alzheimer's Disease Neuroimaging Initiative, Clinical sciences, Neurology, Educational Science, Faculty of Psychology and Educational Sciences, Maastricht University [Maastricht], Universität Heidelberg [Heidelberg] = Heidelberg University, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Georg-August-University = Georg-August-Universität Göttingen, Universität Bonn = University of Bonn, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Antwerp (UA), Vrije Universiteit Brussel (VUB), Aristotle University of Thessaloniki, Karolinska Institutet [Stockholm], Copenhagen University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Hospital de la Santa Creu i Sant Pau, Université de Genève = University of Geneva (UNIGE), Centro San Giovanni di Dio, Fatebenefratelli, Brescia (IRCCS), Università degli Studi di Brescia = University of Brescia (UniBs), Università degli studi di Genova = University of Genoa (UniGe), University of Cologne, Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), VU University Medical Center [Amsterdam], Centre Hospitalier Universitaire de Liège (CHU-Liège), Université de Liège, Centro Hospitalar e Universitário [Coimbra], Université de Lisbonne, University of Gothenburg (GU), F. Hoffmann-La Roche [Basel], Roche Products Ltd, Janssen Research & Development, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Lund University [Lund], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), University of Eastern Finland, Repositório da Universidade de Lisboa, Amsterdam Neuroscience - Neurodegeneration, Radiology and nuclear medicine, Promovendi MHN, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, MUMC+: MA Med Staf Spec Psychiatrie (9), and School of Medicine / Clinical Medicine

Subjects
cognition, Male, Aging, MILD COGNITIVE IMPAIRMENT, ALCOHOL-CONSUMPTION, etiology [Alzheimer Disease], Disease, GUIDELINES, etiology [Cognitive Dysfunction], Alcohol Drinking/adverse effects, ddc:616.89, Cognition, 0302 clinical medicine, Cognitive decline, 10. No inequality, Alzheimer Disease/etiology, Depression (differential diagnoses), Medicine(all), Depression, General Neuroscience, Alzheimer's disease, Biomarkers, IWG-2 criteria, NIA-AA criteria, Prognosis, Risk factors, Neuroscience (all), Developmental Biology, Geriatrics and Gerontology, Neurology (clinical), ASSOCIATION, Middle Aged, CEREBROSPINAL-FLUID BIOMARKERS, 3. Good health, PREVALENCE, adverse effects [Alcohol Drinking], OBESITY, depression, Disease Progression, Female, Risk assessment, Psychology, medicine.medical_specialty, Alcohol Drinking, Hypercholesterolemia, DIAGNOSIS, 03 medical and health sciences, Alzheimer Disease, medicine, Humans, Dementia, Cognitive Dysfunction, Cognitive Dysfunction/etiology, ddc:610, Obesity, Effects of sleep deprivation on cognitive performance, Psychiatry, METAANALYSIS, Aged, Proportional Hazards Models, DECLINE, 030214 geriatrics, Proportional hazards model, [SCCO.NEUR]Cognitive science/Neuroscience, medicine.disease, VASCULAR RISK, Human medicine, 030217 neurology & neurosurgery
Abstract

We investigated whether dementia risk factors were associated with prodromal Alzheimer's disease (AD) according to the International Working Group-2 and National Institute of Aging-Alzheimer's Association criteria, and with cognitive decline. A total of 1394 subjects with mild cognitive impairment from 14 different studies were classified according to these research criteria, based on cognitive performance and biomarkers. We compared the frequency of 10 risk factors between the subgroups, and used Cox-regression to examine the effect of risk factors on cognitive decline. Depression, obesity, and hypercholesterolemia occurred more often in individuals with low-AD-likelihood, compared with those with a high-AD-likelihood. Only alcohol use increased the risk of cognitive decline, regardless of AD pathology. These results suggest that traditional risk factors for AD are not associated with prodromal AD or with progression to dementia, among subjects with mild cognitive impairment. Future studies should validate these findings and determine whether risk factors might be of influence at an earlier stage (i.e., preclinical) of AD., final draft, peerReviewed

Published
2017
Full Text
View/download PDF

7. P4‐122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer’s Disease and Its Influence on Cognitive Decline

Author

Diana Silva, Christine Bastin, Solène Dauby, Isabel Santana, A. Drzezga, F. Verhey, S. Engelborghs, Mira Didic, Inês Baldeiras, E. Rüther, Jens Wiltfang, Myriam Alexander, A. Wientzek-Fleischmann, Åsa K. Wallin, Pieter Jelle Visser, Eric Salmon, E. De Roeck, Flavio Nobili, G. Frisoni, Lutz Frölich, M. Forrest Gordon, Isabelle Bos, Alejo J. Nevado-Holgado, Alberto Lleó, W. Maier, Daniel Alcolea, Yvonne Freund-Levi, Harald Hampel, R. Vandenberghe, J. Kornhuber, P. Scheltens, Preciosa M. Coloma, Alexandre de Mendonça, Gerald Novak, Ellis Niemantsverdriet, Nadia Foskett, S. Galluzzi, Arto Nordlund, Magdalini Tsolaki, Usha Gungabissoon, B.N.M. van Berckel, H. Soininen, Stephanie J. B. Vos, Peter Johannsen, Oliver Peters, Ak. Wallin, and S. Morbelli

Subjects
Gerontology, Epidemiology, business.industry, Health Policy, Disease, Vascular risk, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, business
Published
2016
Full Text
View/download PDF

8. [Multiple sclerosis : therapy update]

Author

Dive D, Solène Dauby, Lommers E, Hansen I, and Maquet P

Subjects
Young Adult, Multiple Sclerosis, Humans
Abstract

Multiple sclerosis is still a severe disease potentially associated with a short- or long-term disability in young adults. Since a few years therapeutic progresses are considerable. New drugs and new therapy rationale considerably improved our knowledge and patient's care. Early treatment is a key within dedicated specialized and multidisciplinary units. Clinical and neuroradiological no evidence of disease activity (NEDA) is a goal, which is more often reached. Patient's evolution and follow-up is completely changed in recent years with more efficacy.La sclérose en plaques (SEP) reste une maladie grave du système nerveux central (SNC), potentiellement responsable d’un handicap, physique ou non, à moyen et long termes, chez des adultes jeunes. Les progrès thérapeutiques au cours des dernières années ont été considérables grâce à l’avènement de nouvelles molécules, mais aussi, et peut-être surtout, de schémas thérapeutiques nettement plus performants. Les progrès des connaissances en immunologie ont eu un impact majeur dans ce domaine. La prise en charge précoce des patients au sein d’unités intégrées et multidisciplinaires est une étape essentielle qui permet de guider l’utilisation rationnelle des médicaments. L’obtention d’une stabilité clinique et neuroradiologique est un défi qui est, de plus en plus souvent, relevé avec un bénéfice majeur pour les patients.

Catalog

Books, media, physical & digital resources
See catalog results